Excerpts from Maybank Kim Eng report
Analyst: Lai Gene Lih, CFA
Shares undervalued; BUY
| Even more attractive after recent sell-off We believe the broader market sell-off due to macro/trade concerns has overshadowed positive developments, such as AEM’s recent upward revision of FY19E revenue guidance to SGD225-250m from SGD180-210m.
Maintain BUY with unchanged TP of SGD1.40 based on 3.1x average FY19-20E P/B. |
||||
Scenario analysis
Even with in a drastic downside scenario of FY19-20E PATMI cuts of 11%/61%, which we believe are unlikely, the shares would be fairly valued at current levels (ROE-g/COE-g fair value SGD0.90, based on 2.1x average FY19-20E P/B).
Our scenario analysis assumes:
|
i) AEM does not win any more orders beyond the SGD209m it has secured by Apr-19; |
Momentum could last into FY20E
|
|
AEM’s FY19E revenue guidance has panned out better than we originally expected in our Jan-19 initiation, despite headwinds faced by its main customer.
According to management, this may be because HDMT is proliferating at a faster-than-expected pace within its customer.
This may also be a signal of the importance of HDMT’s role within the core customer to help reduce testing costs.
Further downside could lead to consolidation
Should our downside scenario play out, AEM would trade at FY20E EV/EBITDA of 5.9x, which is compares favourably to the 7-8x EV/NTM EBITDA that Cohu acquired Xcerra.
In recent years, comparable transactions have occurred at a median 10x of EV/ NTM EBITDA.
Full report here.